# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0...
Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted wea...
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligoData supports VYN201's rapid onset of action and ...
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1...